Nanoparticles for sonodynamic combined personalized immunotherapy of tumors as well as preparation method and application of nanoparticles
By designing HA-Ce6-coated co-loaded L-arginine and Poly(I:C) nanoparticles, combined with acoustic dynamic therapy and NO gas therapy, the toxicity and resistance of colorectal cancer chemotherapy drugs were solved, and the patient achieved the Targeted tumor therapy and activation of immune responses significantly inhibit tumor growth and metastasis.
Patent Information
- Application Number
- CN202410959403.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-17
AI Technical Summary
In the prior art, chemotherapeutic drugs for colorectal cancer have systemic toxicity and drug resistance problems, the immune response rate of immunotherapy is low, and there is a lack of effective combination acoustic dynamics treatment plans, especially in colorectal cancer, no acoustic dynamics is seen. Combination of therapy and NO gas therapy.
A nanoparticle with co-loaded L-arginine and Poly(I:C) coated by HA-Ce6 was designed to form a core by self-assembly of polylysine, L-arginine and TLR3 agonist, transparent Lumolic acid is conjugated with sound-sensitizer to build a shell, achieving the combination of acoustic dynamic therapy, NO gas therapy and tumor immunotherapy, targeting tumor cells and activate immune responses.
Under ultrasound, the nanoparticles generate reactive oxygen killer tumor cells, promote macrophage polarization and NO production, trigger a systemic immune response, inhibit primary tumors, prevent tumor metastasis and recurrence, and significantly improve the therapeutic effect.
Smart Images

Figure CN118903415A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a nanoparticle used for tumor sonodynamic combined with personalized immunotherapy, and a preparation method and application thereof. Background Art
[0002] Colorectal cancer has a very high incidence and mortality rate and is one of the major diseases that threaten human life and health. Statistics from the American Cancer Society in 2021 revealed that the number of new cases and mortality of colorectal cancer ranked third among all cancers, with a growth rate of 5% compared to 2020, and the mortality rates of men and women were 9% and 8%, respectively. Surgery, radiotherapy and chemotherapy are currently the main means of treating colorectal cancer, but the systemic toxicity and drug resistance of chemotherapy drugs are still serious. In contrast, immunotherapy that activates the patient's own immune system to kill tumor cells can largely solve these problems. Although immunotherapy has broad prospects, considering the large differences in patients' immune systems, low immune response rates, and unfavorable immune microenvironment of tumors, a variety of immune combination therapy strategies that combine immunotherapy with other therapies have received widespread attention. As a non-invasive tumor treatment method, sonodynamic therapy (SDT) has significant advantages such as good controllability, high precision and strong penetration. Under the action of ultrasound, sonosensitizers are activated to produce a large amount of reactive oxygen species, which promotes the apoptosis of tumor cells. However, common sonosensitizers such as Ce6 have poor water solubility and require the design of reasonable delivery strategies.
[0003] NO is a very important gas molecule in the human body, and it plays the role of a messenger molecule in the cardiovascular, nervous, and immune systems. In the tumor microenvironment, a variety of cells have the ability to produce NO, including fibroblasts, antigen-presenting cells, macrophages, and NK cells. Among these cells, macrophages are a key source of NO synthesis. The expression of highly inducible nitric oxide synthase (iNOS) in M1 macrophages is a prerequisite for NO production. Endogenous NO produced by iNOS can regulate the immune system in a dose-dependent manner, thereby affecting tumor progression. Studies have found that high concentrations of NO inhibit the development of malignant tumors by inducing cell apoptosis, delaying angiogenesis, and inhibiting multidrug resistance. Low concentrations of NO can also promote the infiltration of T cells and recruit and activate immune effector cells. L-arginine is a natural NO donor that can release NO in the presence of iNOS or ROS. Since the content of L-arginine in tumor tissue is low, exogenous supplementation of L-arginine can exert an anti-tumor effect by releasing a large amount of NO. In recent years, NO-based anti-tumor therapy has attracted more and more attention. However, there are no reports on the use of sonodynamic therapy combined with NO gas to treat colorectal cancer. Summary of the invention
[0004] The purpose of the present invention is to provide a nanoparticle for tumor sonodynamic combined with personalized immunotherapy and its preparation method and application, so as to solve the problems existing in the above-mentioned prior art. By constructing a nanoparticle coated with HA-Ce6 and co-loaded with L-arginine and Poly (I: C), combined sonodynamic therapy, NO gas therapy and tumor immunotherapy are achieved, which can effectively treat tumors and inhibit tumor metastasis and recurrence.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] The invention provides a nanoparticle for sonodynamic combined with personalized immunotherapy of tumors. The nanoparticle is a double-layer core-shell structure nanoparticle consisting of an inner core and an outer shell. The inner core of the nanoparticle comprises polylysine, L-arginine and a TLR3 agonist, and the outer shell of the nanoparticle comprises hyaluronic acid and a sonosensitizer.
[0007] Preferably, the nanoparticle core is self-assembled by poly-lysine, L-arginine and TLR3 agonist, and the nanoparticle shell is constructed by conjugating the sonosensitizer to hyaluronic acid. More preferably, the TLR3 agonist is Poly(I:C) and the sonosensitizer is Ce6, but the TLR3 agonist and sonosensitizer are not limited to the above compounds.
[0008] The present invention also provides a method for preparing the nanoparticles, comprising the following steps:
[0009] The nanoparticle core was constructed by mixing poly-lysine, L-arginine and TLR3 agonist for self-assembly;
[0010] The sonosensitizer is conjugated to hyaluronic acid to prepare the nanoparticle shell;
[0011] The nanoparticle core and the nanoparticle shell are dissolved in water respectively, mixed and stirred, centrifuged, washed, resuspended, and then ultrasonically dispersed to obtain multifunctional sonodynamic nanoparticles with a double-layer core-shell structure consisting of an inner core and an outer shell.
[0012] Preferably, the method for preparing the nanoparticle core specifically comprises the following steps:
[0013] The TLR3 agonist aqueous solution is added dropwise to the L-arginine aqueous solution and the polylysine aqueous solution, shaken at room temperature for self-assembly, centrifuged and washed to obtain the nanoparticle core; wherein the volume ratio of the TLR3 agonist aqueous solution, the L-arginine aqueous solution and the polylysine aqueous solution is 60:(80-110):(110-130).
[0014] Preferably, the concentration of the TLR3 agonist aqueous solution is 2 mg / mL, the concentration of the L-arginine aqueous solution is 5 mg / mL, and the concentration of the polylysine aqueous solution is 2 mg / mL;
[0015] The shaking conditions are: rotation speed 3000 rpm, time 30-60 min; the centrifugal conditions are: rotation speed 10000 rpm, time 10-20 min.
[0016] Preferably, the method for preparing the nanoparticle shell specifically comprises the following steps:
[0017] The intermediate product I is prepared by mixing hyaluronic acid, adipic acid dihydrazide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, dialyzing and freeze-drying.
[0018] N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride are reacted with the sonosensitizer, and then reacted with the intermediate product I, dialyzed, and freeze-dried to obtain the nanoparticle shell.
[0019] Preferably, the mass ratio of the hyaluronic acid, the adipic acid dihydrazide and the 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is 100:(200-240):(20-30);
[0020] The mass ratio of the N-hydroxysuccinimide, the 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and the sonosensitizer is 30:(35-45):30, and the mass ratio of the sonosensitizer to the intermediate product I is 30:100.
[0021] Preferably, the volume ratio of the nanoparticle core to the nanoparticle shell is 2:3;
[0022] The mixing conditions are: rotation speed 500 rpm, stirring time 10-12h;
[0023] The ultrasonic conditions are: using a 3 mm probe, a power of 20%, a treatment time of 1 min, and ultrasonicating for 5 s every 5 s.
[0024] The present invention also provides the use of the nanoparticles in any of the following:
[0025] (1) Application in the preparation of products that enhance the body's immune response;
[0026] (2) Application in the preparation of products for treating tumors or inhibiting tumor metastasis and recurrence.
[0027] Furthermore, the above products include drugs, drug carriers, etc.
[0028] Preferably, the tumor comprises colorectal cancer.
[0029] The present invention discloses the following technical effects:
[0030] The nanoparticles prepared by the present invention for tumor sonodynamic combined with personalized immunotherapy have an outer layer of HA-Ce6, a hyaluronic acid layer conjugated with sonosensitizer Ce6, and the inner core of the nanoparticles is self-assembled by TLR3 agonist Poly(I:C), L-arginine and polylysine. The nanoparticles bind to the CD44 receptor overexpressed by tumor cells through the hyaluronic acid shell to target the tumor. Ce6 can generate reactive oxygen to kill tumors and produce specific tumor-associated antigens under the action of ultrasound. Poly(I:C) can promote the polarization of tumor-associated macrophages in the tumor microenvironment to M1 type. M1 type macrophages use L-arginine to produce and release NO. NO can further recruit and activate immune effector cells while inhibiting the growth of tumor cells, thereby realizing sonodynamic combined with NO gas for tumor immunotherapy.
[0031] The nanoparticles prepared by the present invention for tumor sonodynamic combined with personalized immunotherapy can induce a systemic immune response, inhibit primary tumors, produce immune memory effects, and prevent tumor metastasis and recurrence. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0033] Figure 1 The particle size distribution diagram (A), zeta potential distribution diagram (B), transmission electron microscopy diagram (C), and UV scanning spectrum diagram (D) of NP, Ce6-NP and free drug between 200-800nm of the NP prepared in Example 1 of the present invention and the nanoparticle Ce6-NP for sonodynamic combined personalized immunotherapy coated with HA-Ce6 shell;
[0034] Figure 2 The consumption of DPBF probe caused by different concentrations (A) and different ultrasonic times (B) of Ce6-NP and free Ce6 prepared in Example 1 of the present invention under ultrasound;
[0035] Figure 3 Cumulative release curves of Ce6 (A) and Poly (I: C) (B) of Ce6-NP prepared in Example 1 of the present invention in PBS buffers at pH 7.4 and 6.5 with or without HAase;
[0036] Figure 4 The representative flow cytometric histogram and bar graph of Ce6 uptake by cells after CT26 cells were co-incubated with Ce6-NPs prepared in Example 1 of the present invention and free drugs for 1, 2, and 6 hours;
[0037] Figure 5 The cell viability bar graph (A) of NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention after co-incubation with CT26 cells with or without ultrasound at different concentrations, the bar graph of ATP contained in the supernatant (B), the bar graph of HMGB1 expression in CT26 cells (C) and a representative flow cytometry histogram (D);
[0038] Figure 6 The confocal microscopy results and representative flow cytometry graphs are used to measure the production of reactive oxygen species (ROS) by CT26 cells under ultrasound using the DCFH-DA fluorescent probe for NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention;
[0039] Figure 7 The bar graph and representative flow cytometric histogram of L-Arg uptake by RAW264.7 cells after incubation with NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention for 1, 2 and 6 hours;
[0040] Figure 8 The representative flow cytometric graphs and corresponding bar graphs of the phenotype of BMDMs detected by flow cytometry after incubation of NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention with BMDMs;
[0041] Fig. 9 The confocal microscopy results and representative flow cytometry graphs of the production of NO by RAW264.7 cells using the DAF-FM DA fluorescent probe to measure the NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention;
[0042] Fig.10 Representative flow cytometric graphs and corresponding bar graphs of the expression of CD40, CD80, CD86 and MHC I molecules by BMDCs detected by flow cytometry after incubation of NPs, Ce6-NPs and free drugs prepared in Example 1 of the present invention with BMDCs;
[0043] Fig.11 The in vivo imaging results after tail vein injection of Ce6-NP prepared in Example 1 and free drugs were observed using a small animal in vivo imaging instrument, as well as the in vitro fluorescence signals of various tissues 24 hours after administration (A), and the fluorescence intensity of Ce6 in mouse tumor tissues at different time points after administration (B);
[0044] Fig.12 The tumor growth curve (A), survival curve (B) and body weight curve (C) of NP, Ce6-NP and free drug prepared in Example 1 after treating unilateral tumor-bearing mice with or without ultrasound.
[0045] Fig.13 The growth curves of the proximal tumor (A) and distal tumor (B), the survival curve (C) and the body weight curve (D) of the mice bearing bilateral tumors after the NP, Ce6-NP and free drug prepared in Example 1 were treated with or without ultrasound.
[0046] Fig.14 H&E staining images of the main organs of mice after treatment;
[0047] Fig.15 The effector memory CD4 in spleen cells of tumor-bearing mice after 85 days of ultrasound treatment with Ce6-NP prepared in Example 1 + TEM(A) and CD8 + TEM (B) proportional representative flow cytometry and bar graph;
[0048] Fig.16 Photos (A) and bar graphs (B) as well as H&E staining results (C) of lung tissue tumor nodules in CT26 tumor-bearing mice cured by Ce6-NP prepared in Example 1 14 days after tail vein injection of tumor cells. DETAILED DESCRIPTION
[0049] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0050] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0051] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0052] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0053] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0054] The raw materials used in the following examples can all be purchased through commercial channels.
[0055] The "room temperature" mentioned above refers to 20-30°C unless otherwise specified.
[0056] The present invention provides a preparation method and application of nanoparticles for sonodynamic combined personalized immunotherapy of tumors. The outer layer of the nanoparticles is a hyaluronic acid layer conjugated with sonosensitizer Ce6, and the inner core is self-assembled by TLR3 agonist Poly (I: C), L-arginine (L-Arg) and polylysine (PLL). Ce6 is conjugated to the hyaluronic acid molecule to enhance the tumor targeting ability. Ce6 can generate reactive oxygen to kill tumors and produce specific tumor-associated antigens under ultrasound. Poly (I: C) can promote tumor-associated macrophages from immunosuppressive M2 type to anti-tumor M1 type. M1 type macrophages overexpress iNOS and can use L-arginine to produce anti-tumor small molecule NO, thereby realizing sonodynamic combined with NO gas for tumor immunotherapy. The above technical scheme is further described below with specific examples.
[0057] Example 1 A method for preparing nanoparticles for sonodynamic combined with personalized immunotherapy
[0058] (1) preparing a poly-lysine (MW 30000-70000) aqueous solution (2 mg / mL), an L-arginine aqueous solution (5 mg / mL), and a Poly (I:C) aqueous solution (2 mg / mL), taking 100 μL of the L-arginine aqueous solution and mixing it with 120 μL of the poly-lysine aqueous solution, then adding 60 μL of the Poly (I:C) aqueous solution dropwise, shaking at 3000 rpm for 45 min at room temperature, centrifuging the solution (10000 rpm, 10 min) and washing it with deionized water to obtain a precipitate as the nanoparticle core (NP);
[0059] (2) 100 mg of hyaluronic acid (10 kDa) and 220 mg of adipic acid dihydrazide (ADH) were dissolved in 10 mL of ultrapure water, stirred for 30 min, and then 25 mg of 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl) was added. During the reaction, HCl was used to maintain the pH at 4.8. After 24 h of reaction, NaOH was added to adjust the pH to 7.0 to stop the reaction. HA-ADH was purified by dialyzing in ultrapure water for 24 h using a dialysis bag (MW=3500D) and lyophilized.
[0060] 30 mg N-hydroxysuccinimide (NHS) and 40 mg EDC·HCl were added to a dimethylformamide (DMF) solution of Ce6 (10 mL, 3 mg / mL) and stirred at room temperature for 4 h to obtain a Ce6-NHS solution. Then, 10 mL HA-ADH aqueous solution (10 mg / mL) was added to the Ce6-NHS solution and stirred at room temperature for 24 h. Finally, the entire solution was dialyzed in DMF and ultrapure water for 24 h, and lyophilized to obtain HA-Ce6.
[0061] (3) Mix 300 μL of HA-Ce6 aqueous solution (containing 0.5 mg / mL of Ce6) and 200 μL of NP aqueous solution (containing 1 mg / mL of Poly(I:C)), stir at 500 rpm at room temperature for 10-12 h, centrifuge (10,000 rpm, 10 min), wash with deionized water, resuspend in ultrapure water, and ultrasonicate for 1 min (using a 3 mm probe, a power of 20%, and ultrasonicate for 5 s every 5 s) to completely disperse it in the solution to obtain Ce6-NP.
[0062] Test Example 1
[0063] 1. Particle size, potential measurement and morphology characterization of the nanoparticles Ce6-NP prepared in Example 1
[0064] The particle size and potential were analyzed by a particle size analyzer; the morphology of the nanoparticles was characterized by a transmission electron microscope; and the successful encapsulation of Poly(I:C) and Ce6 was verified by scanning the NP and HA-Ce6 aqueous solution in the wavelength range of 200-800nm using a UV-visible spectrophotometer.
[0065] like Figure 1 As shown in Figure 1, the average particle size of NP is 161.50±3.12nm, and the average particle size of Ce6-NP is 187.90±4.38nm. The particle size is normally distributed. The morphology of nanoparticles was observed by transmission electron microscopy (see Figure 1 The results are consistent with those measured by the particle size analyzer, indicating that Ce6-NP is uniformly spherical, of appropriate size, and has a clear core-shell structure. The Zeta potential of NP was further measured by the particle size analyzer to be 27.67±1.22mV. After being coated with the negatively charged HA-Ce6 shell, the Zeta potential of Ce6-NP changed to -2.802±0.58mV (see Figure 1 (middle B).
[0066] 2. Determination of the encapsulation efficiency and drug loading of Ce6, Poly(I:C) and L-Arg in the nanoparticles Ce6-NP prepared in Example 1
[0067] The mass of Ce6-NP was obtained by freeze-drying, and the absorbance of the supernatant obtained by centrifuging Ce6-NP at the characteristic peaks of Ce6 and Poly(I:C) was measured by UV-visible spectrophotometer (see Figure 1 (middle D).
[0068] The content of L-Arg was determined by the α-naphthol method: 1 mL of NaOH solution (40 g / L), 1 mL of methylnaphthol n-propanol solution (80 g / L) and 1 mL of diacetyl n-propanol solution (0.5 mg / L) were added to a test tube, and 1 μL of the sample was added. After color development at 30°C in a water bath for 5 min, the absorbance was measured at 545 nm using a UV-visible spectrophotometer (see Figure 1 (middle D).
[0069] The formula for calculating the encapsulation efficiency is:
[0070] Drug encapsulation efficiency (%) = (dose - mass of drug in supernatant) / dose × 100%
[0071] Drug loading (%) = (dose - mass of drug in supernatant) / total mass of nanoparticles × 100%
[0072] The results showed that the encapsulation efficiency of Ce6 in Ce6-NP was 49.0±3.96%, and the drug loading was 3.3%±0.44%; the encapsulation efficiency of Poly(I:C) was 56.0±0.82%, and the drug loading was 7.5%±0.53%; the encapsulation efficiency of L-Arg was 51.7±2.71%, and the drug loading was 28.7%±1.5%, indicating that the nanoparticles have a high drug encapsulation capacity.
[0073] Test Example 2
[0074] The in vitro sonodynamic effect of the nanoparticle Ce6-NP prepared in Example 1 of the present invention was investigated: the generation of reactive oxygen species in free Ce6 and Ce6-NP under ultrasonic and non-ultrasonic conditions was analyzed using a DPBF probe. Free drug and Ce6-NP with different Ce6 equivalent concentrations were prepared, and after adding a DPBF probe (50 μM), the mixture was ultrasonically excited (1.0 MHz, 1.0 W cm -2 , 50% duty cycle) for 5 min. Finally, the absorbance intensity of each group at a wavelength of 398 nm was measured by a UV-visible spectrophotometer. The DPBF consumption was calculated according to the following formula: DPBF consumption (%) = (absorbance before DPBF irradiation - absorbance after DPBF irradiation) / absorbance before DPBF irradiation × 100%
[0075] The results under different Ce6 concentrations and different ultrasound times are as follows Figure 2 As shown, it can be seen that Ce6-NP has better reactive oxygen generation ability than free Ce6, that is, better sonodynamic effect. Because Ce6 is a hydrophobic molecule, it is unevenly dispersed in the solution, and after being connected with HA and coated on the surface of the nanoparticles, it can be more evenly dispersed in the solution and more stably accept the action of ultrasound. With the increase of ultrasonic time and Ce6 concentration, the more reactive oxygen is produced, the more DPBF is consumed. When the Ce6 concentration is 8μg / mL and the ultrasonic time is 5 minutes, the DPBF consumption rate of the Ce6-NP group reaches more than 35%, which is significantly higher than the consumption rate of the free Ce6 group. Experimental research found that whether it is further increasing the Ce6 concentration to 10μg / mL or extending the ultrasonic time to 10 minutes, the consumption of DPBF did not increase significantly. Therefore, the present invention determines that the subsequent Ce6 dosage is 8μg / mL and the ultrasonic treatment time is 5 minutes.
[0076] Test Example 3
[0077] The dialysis bag method was used to determine the drug release of nanoparticles Ce6-NP. The specific method is: take 200μL Ce6-NP solution and place it in a dialysis bag (MW=3500D) and seal it, then place the dialysis bag in 10mL, pH=6.5 or pH=7.4 PBS buffer solution containing or not containing hyaluronidase (HAase), and put it in a shaker for shaking at 37°C and 150rpm. Take out all the release solution regularly and add the same volume of fresh buffer solution, measure the absorbance of Ce6 and Poly (I: C) in the test solution by UV-visible spectrophotometer, and calculate the drug release amount by standard curve.
[0078] like Figure 3 As shown in the figure, at 12 h, the cumulative release rates of Ce6 and Poly(I:C) in PBS buffer solution with pH = 6.5 and containing HAase reached 20% and 40%, respectively, which were significantly higher than the drug release in PBS buffer solution with pH = 7.4, showing obvious responsiveness to the tumor microenvironment (acidic and containing HAase); while the release amount of Ce6 was relatively low, which may be because Ce6 was connected to the high molecular weight hyaluronic acid through chemical bonds, and even after being degraded by HAase, some HA-Ce6 fragments were still unable to pass through the dialysis bag, while Poly(I:C) is a small molecule and can more easily pass through the dialysis bag.
[0079] Test Example 4
[0080] Determination of tumor cell uptake of nanoparticles Ce6-NP prepared in Example 1:
[0081] CT26 mouse colon cancer cells were digested and centrifuged at 5 × 10 5 Cells were inoculated at a density of 1.5 cells / mL in a 12-well plate. After the cells were cultured overnight, the culture medium was discarded and the culture medium containing Free (a mixture of free Ce6, Poly (I:C) and L-Arg) and Ce6-NP was re-added (the equivalent Ce6 concentration was 8 μg / mL). The preparation was incubated with the cells for 1, 2, and 6 h, the culture medium was discarded, and the cells were washed twice with PBS. The cells were then collected and sieved, and the drug uptake efficiency of CT26 cells was detected by flow cytometry.
[0082] Representative flow cytometry histograms of Ce6 uptake by CT26 cells at different incubation times are shown in Figure 2. Figure 4 As shown, the results showed that compared with the Free group, the Ce6-NP group enabled CT26 cells to have a higher uptake rate of Ce6, reaching 87.7% 6 hours after administration, proving the tumor targeting brought by the HA shell.
[0083] Test Example 5
[0084] The nanoparticles Ce6-NP prepared in Example 1 were tested for their ability to kill tumor cells and induce immunogenic cell death (ICD) under ultrasound:
[0085] Free (mixture of free Ce6, Poly(I:C) and L-Arg), NP and Ce6-NP were incubated with CT26 cells at different Ce6 equivalent concentrations for 24 h. The US group was given 5 min of ultrasound (1.0 MHz, 1.0 W cm -2 , 50% duty cycle). The CCK8 method was used to analyze the effects of various treatments on the activity of CT26 cells. At the same time, the cells were stained with HMGB1-PE antibody, the expression of cell HMGB1 was analyzed by flow cytometry, and the level of cell ATP secretion was determined by ATP kit to investigate the cell immunogenic death (ICD) induced by nanoparticles under ultrasound.
[0086] like Figure 5 As shown in A, when there is no ultrasound, the survival rate of CT26 cells is always high with the increase of drug concentration in each group, indicating that the drug is non-toxic to cells in the absence of ultrasound. The cell survival rate of the NP group is slightly lower than that of the Free group, which may be due to the slight toxicity caused by the strong positive charge of the nanoparticles. Ce6-NP also shows slight toxicity with the increase of Ce6 dose. On the one hand, due to the dose-dependent cytotoxic effect of Ce6 itself, and the targeting function brought by hyaluronic acid, the cells take up more Ce6 than the Free group. At the same time, HAase in the tumor microenvironment will degrade the HA shell and expose the strong positive core NP, which also explains that the cytotoxic trend of Ce6-NP is consistent with that of NP as a whole. After ultrasound, the Ce6-NP group caused the survival rate of CT26 cells to drop below 40% at a concentration of 8μg / mL of Ce6, indicating that sonodynamic therapy based on Ce6-NP can significantly kill tumor cells. Extracellular ATP, as a recognized "find me" signal for DCs and macrophages, can recruit immune cells to the tumor site, thereby regulating tumor antigen cross-presentation and macrophage polarization; HMGB1 can bind to pattern recognition receptors expressed by various immune cells, including TLR4, and is an important component of ICD-induced immunogenicity. Representative flow cytometry and quantitative analysis results are shown in Figure 2. Figure 5 As shown in BD, under the action of ultrasound, the positive rate of HMGB1 in the Ce6-NP group can reach 55.8%, and the ATP secretion level can reach 26.7nM, which is significantly higher than that in the Free group, which is consistent with the cytotoxic results of CCK8, proving that the sonodynamic killing effect of Ce6-NP can induce ICD in tumor cells, thereby further inducing the anti-tumor effect of immune cells.
[0087] Test Example 6
[0088] Determination of the generation of reactive oxygen species (ROS) in tumor cells by nanoparticles Ce6-NP prepared in Example 1 under ultrasound:
[0089] DCFH-DA was used as a ROS fluorescent probe. CT26 cells were plated at 5 × 10 5 The cells were seeded in a 12-well plate at a density of 10 cells / mL. After 24 h, PBS, Free (a mixture of free Ce6, Poly(I:C) and L-Arg), NPs and Ce6-NPs were co-incubated with CT26 cells. After 6 h of incubation, the cells were replaced with medium containing DCFH-DA (1 mM) and incubated for 30 min. The cells were washed three times with PBS and then subjected to 5 min of ultrasound (1.0 MHz, 1.0 W cm -2 , 50% duty cycle), and the intracellular ROS fluorescence intensity was detected by flow cytometry and laser confocal microscopy.
[0090] Representative flow cytometry images and microscope photos of each group are shown in Figure 6 As shown, it can be seen that Ce6-NP can promote the generation of more reactive oxygen species in tumor cells under ultrasound compared with the Free group, and has a better sonodynamic effect. At the same time, the fluorescence intensity decreases after the addition of antioxidant Vc.
[0091] Test Example 7
[0092] Study on the promotion of macrophage uptake by nanoparticles Ce6-NP prepared in Example 1:
[0093] RAW264.7 macrophages were digested and centrifuged at 5 × 10 5 The cells were seeded in a 12-well plate at a density of 1.5 cells / mL. After the cells were cultured overnight, the medium was discarded and the medium of Free (a mixture of free Ce6, Poly (I:C) and L-Arg), NP and Ce6-NP (L-Arg was labeled with FITC, and the equivalent L-Arg concentration was 70 μg / mL) was added again and incubated with the cells for 1, 2 and 6 hours, respectively. The medium was discarded and the cells were washed twice with PBS. The cells were then collected and screened and the drug uptake efficiency of RAW264.7 cells was detected by flow cytometry. Representative flow cytometric histograms and bar graphs are shown in Figure 2. Figure 7 As shown, compared with the free drug group, RAW264.7 cells took up more NP and Ce6-NP, and the uptake ratio of Ce6-NP group was slightly lower than that of NP, which may be due to the protection of HA-Ce6 shell shielding the positive charge on the surface of nanoparticles.
[0094] Test Example 8
[0095] Study on the effect of Ce6-NP prepared in Example 1 on promoting polarization of macrophage M1:
[0096] BMDMs (5×10 5 BMDMs-specific culture medium containing PBS, Free (a mixture of free Ce6, Poly (I: C) and L-Arg), NP and Ce6-NP was added to the cells (100 cells / mL), and the culture was continued for 24 hours. The cells were collected and washed once with PBS. CD11b-PE and F4 / 80-eFlour450 antibodies were incubated at 4°C for 30 minutes, and PBS was washed once; 0.1 mL of IC fixation buffer was added, and the cells were incubated at room temperature in the dark for 60 minutes, and 1 mL of freshly prepared 1× permeabilization solution was washed once, and the cells were centrifuged and the supernatant was discarded. After adding CD206-APC antibody diluted in 1× permeabilization solution, the cells were incubated at room temperature in the dark for 60 minutes, and the cells were washed once with 1× permeabilization solution, and the supernatant was discarded after centrifugation. After resuspending in 0.3 mL PBS, macrophages (CD11b + ) in the presence of surface markers F4 / 80 and CD206, with F4 / 80 + CD206 + M2 macrophage population, F4 / 80 + CD206- is the M1 macrophage population. Figure 8 As shown, both NP and Ce6-NP can induce an increase in the proportion of M1 macrophages and reduce the proportion of M2 macrophages, thereby reversing the macrophage phenotype and inducing the ability of macrophages to kill tumor cells.
[0097] Test Example 9
[0098] Determination of the effect of the nanoparticles Ce6-NP prepared in Example 1 on promoting the production of NO in macrophages:
[0099] DAF-FM DA was used as a fluorescent probe for NO. RAW264.7 cells were plated at 5 × 10 cells per well. 5 The cells were seeded at a density of 100 cells / mL in a 12-well plate. After 24 hours, PBS, Free (a mixture of free Ce6, Poly(I:C) and L-Arg), NP and Ce6-NP were added to the cells for co-incubation. After 6 hours of incubation, the culture medium containing DAF-FM DA (20 μM) was replaced and incubated for 30 minutes. After washing the cells three times with PBS, the NO fluorescence intensity in the cells was detected by flow cytometry and laser confocal microscopy. Microscope photos and representative flow cytometric images of each group are shown in Figure 2. Fig. 9 As shown, compared with the Free group, the NPs containing L-Arg and Ce6-NPs groups could promote macrophages to produce more NO and exert anti-tumor effects.
[0100] Test Example 10
[0101] Determination of the ability of the nanoparticle Ce6-NP prepared in Example 1 to promote the maturation and activation of bone marrow-derived dendritic cells (BMDCs):
[0102] BMDCs cultured on the sixth day were collected and plated in 12-well plates (5×10 5 Cells / mL), 12 hours later, BMDCs-specific culture medium containing PBS, Free (mixture of free Ce6, Poly (I: C) and L-Arg), NP and Ce6-NP was added, and culture was continued for 24 hours, and the cells were collected and washed once with PBS. CD40, CD80, CD86 and MHC I antibodies were used for staining at 4°C for 30 minutes, centrifuged and washed, and resuspended with 300 μL 4% paraformaldehyde. After sieving, the expression levels of CD40, CD80, CD86 and MHC I molecules on the surface of BMDCs were determined by flow cytometry.
[0103] Representative flow cytometry graphs and corresponding bar graphs are shown below: Fig.10 As shown, compared with the PBS group and the Free group, NP and Ce6-NP significantly enhanced the expression of CD40 and CD80 molecules, and the proportion of double positive cells reached 72.4% and 78.9%, respectively, and the proportion of CD86 positive cells reached 52.7% and 55.2%, respectively, indicating that NP and Ce6-NP loaded with Poly (I: C) and L-Arg have good ability to induce BMDCs activation and maturation. In addition, the expression level of MHC I molecules was also significantly improved under the induction of NP and Ce6-NP, from 3.84% in the PBS group to about 20%, reflecting the role of NP and Ce6-NP in promoting BMDCs antigen presentation.
[0104] Test Example 11
[0105] Study on the distribution and tumor targeting ability of nanoparticle Ce6-NP prepared in Example 1:
[0106] Female BALB / C mice aged 6-8 weeks were selected and depilated. CT26 cells (1×10 6 The tumor-bearing mouse model was established by 3 At the same time, the mice were randomly divided into FreeCe6 group and Ce6-NP group, with 3 mice in each group. The in vivo fluorescence distribution of Ce6 was observed using a small animal living imaging device at 6, 12, 24, 48, 72, and 96 h after tail vein injection. At the same time, the mice were dissected 24 h after administration to observe the fluorescence intensity of Ce6 in various organs and tumor tissues of the mice.
[0107] The results of in vivo imaging and the in vitro fluorescence signals of each tissue are as follows Fig.11 As shown, Ce6-NP has obvious accumulation in the tumor site 12 hours after tail vein administration, and quantitative analysis shows that drug targeting accumulation reaches the maximum after 24 hours of administration, which may be because the HA coating enables the nanoparticles to bind to the CD44 receptor overexpressed by tumor cells, thereby effectively targeting the tumor. The drug is not completely metabolized until 96 hours after administration, so the present invention determines to give the drug every 4 days and perform ultrasonic treatment 12 hours and 24 hours after administration.
[0108] Test Example 12
[0109] The nanoparticle Ce6-NP obtained in Example 1 of the present invention was tested for its anti-tumor effect in vivo. The specific method is as follows: female BALB / C mice aged 6-8 weeks were selected for the efficacy experiment. After depilation, CT26 cells (1×10 6 The tumor-bearing mouse model was constructed by 3 The mice were randomly divided into 7 groups: PBS, Free (a mixture of free Ce6, Poly(I:C) and L-Arg), NP, Ce6-NP, Free+US, NP+US and Ce6-NP+US groups, with 9 mice in each group. The equivalent Ce6 dose was 2.5 mg / kg, the equivalent Poly(I:C) dose was 5.7 mg / kg, and the ultrasound conditions of the ultrasound group were 1.0 MHz, 1.0 W cm -2 , 50% duty cycle, continuous ultrasound of the tumor site for 5 minutes. The day of administration was recorded as day 0, and each group of preparations were injected into the tail vein on days 0, 4, 8, and 12. Ultrasound treatment was given 12h and 24h after each injection. The mice were observed every two days, and the long and short diameters of the tumor were measured with a vernier caliper. When the tumor volume was greater than 2000mm 3 The mice were killed at 4 pm and the tumor volume was calculated as follows:
[0110]
[0111] The results are as follows Fig.12 As shown, from Fig.12 As can be seen in Figure A, neither the non-ultrasound treatment group nor the NP+US group could inhibit tumor growth; while the tumor volume of mice in the Free group increased rapidly even under ultrasound, which is because the free drug cannot target the tumor site and is rapidly metabolized in the mouse body. The Ce6-NP+US group showed a significant effect in inhibiting tumor growth. Fig.12 As shown in Figure B, the mice in the other groups died within 38 days, but all 9 mice in the Ce6-NP+US group survived until the 48th day. Fig.12 As shown in C, the mouse weight curve shows that there is no significant change in the body weight of each preparation group, indicating that each preparation has good biosafety.
[0112] Test Example 13
[0113] The inhibitory effect of the nanoparticle Ce6-NP obtained in Example 1 on distal tumors in mice was further investigated. A bilateral tumor-bearing mouse model was constructed in the same manner as in Experimental Example 9: CT26 cells (1.5×10 6 When the right tumor volume is 80mm 3 The day before the drug administration, CT26 cells (1.5×10 6 Each group of mice had 6 mice in each group. The right tumor of each group of mice was treated with the same treatment as in Experimental Example 9. When the tumor volume was greater than 2000 mm 3 The mice were killed at 4 000 rpm and the growth of proximal and distal tumors was observed every two days.
[0114] The results are as follows Fig.13 As shown in the figure, it can be seen that after treatment with Ce6-NP+US, the proximal and distal tumors of tumor-bearing mice were significantly inhibited, and the distal tumors hardly grew, reflecting that nanoparticles combined with ultrasound can significantly inhibit tumor recurrence. Even when the tumor volume was large, 4 mice in the Ce6-NP+US group were still completely cured, and the remaining 2 mice survived until the 32nd day without significant changes in body weight, further indicating that the nanoparticles have good biosafety and can prolong the survival of tumor-bearing mice.
[0115] Test Example 14
[0116] Safety evaluation of the nanoparticle Ce6-NP obtained in Example 1:
[0117] In order to further evaluate the safety of nanoparticles on tissues and organs, the mice in each group were dissected on the 14th day after administration in Experimental Example 9, and the heart, liver, spleen, lung, and kidney were collected for H&E staining.
[0118] like Fig.14 As shown, no lesions were found in the major organs of mice in each group, indicating that the nanoparticles used for tumor sonodynamic therapy combined with personalized immunotherapy have good biocompatibility and no toxic side effects on normal tissues and organs.
[0119] Test Example 15
[0120] Anti-tumor immune memory determination of nanoparticle Ce6-NP obtained in Example 1:
[0121] Observe the mice cured in the Ce6-NP+US group in Test Example 9. On the 85th day after administration, the spleen was collected, the red blood cells were ground and lysed to obtain a single cell suspension, and CD4-FITC, CD8a-PE, CD62L-PerCP-Cy5.5, CD44-APC, CD3e-eflour450 antibodies were added and incubated at 4°C for 30 minutes, washed once with PBS, and finally resuspended with 4% paraformaldehyde, and the effector memory T cells (CD44 + CD62L - )Proportion.
[0122] The results are as follows Fig.15 As shown in A and B, in the control group, CD4 + TEM and CD8 + The proportions of TEM were 42.6% and 38.4%, respectively, while the CD4 + TEM and CD8 + The TEM ratio was significantly higher than that of the control group, which were 56.5% and 52.9% respectively. The results showed that the nanoparticles of Example 1 could induce an effective immune memory effect under the action of ultrasound.
[0123] Test Example 16
[0124] Study on the anti-tumor lung metastasis of nanoparticle Ce6-NP obtained in Example 1:
[0125] The skin near the right lower limb of BALB / C female mice aged 6-8 weeks was depilated and CT26 cells (1×10 6 cells / cell), when the tumor volume grows to 50mm 3 The day of administration was recorded as day 0. Ce6-NP was injected into the tail vein on days 0, 4, 8, and 12. Ultrasound treatment was given 12 and 24 hours after each injection. On the 30th day of treatment, three completely cured mice and BALB / C female mice of the same age were selected as the control group and injected with 3×10 5 CT26 cells were used, and the lung tissues of the mice were collected 14 days later, and the lung nodules were observed, photographed, and subjected to H&E staining.
[0126] H&E results Fig.16 As shown in the figure, there were a large number of obvious tumor metastases in the control group, and there were almost no visible tumor metastases in the mice cured by Ce6-NP+US group. This shows that mice treated with Ce6-NP+US can produce immune memory effects to inhibit tumor metastasis.
[0127] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A nanoparticle for tumor sonodynamic combined with personalized immunotherapy, characterized in that: The nanoparticles are double-layer core-shell nanoparticles consisting of an inner core and an outer shell. The inner core of the nanoparticles comprises polylysine, L-arginine and a TLR3 agonist, and the outer shell of the nanoparticles comprises hyaluronic acid and a sonosensitizer.
2. The nanoparticles according to claim 1, characterized in that The nanoparticle core is self-assembled by poly-lysine, L-arginine and TLR3 agonist, and the nanoparticle shell is constructed by conjugating the sonosensitizer to hyaluronic acid.
3. A method for preparing nanoparticles according to claim 1 or 2, characterized in that: The following steps are involved: The nanoparticle core was constructed by mixing poly-lysine, L-arginine and TLR3 agonist for self-assembly; The sonosensitizer is conjugated to hyaluronic acid to prepare the nanoparticle shell; The nanoparticle core and the nanoparticle shell are dissolved in water respectively, mixed and stirred, centrifuged, washed, resuspended, and then ultrasonically dispersed to obtain multifunctional sonodynamic nanoparticles with a double-layer core-shell structure consisting of an inner core and an outer shell.
4. The preparation method according to claim 3, characterized in that: The preparation method of the nanoparticle core specifically comprises the following steps: The TLR3 agonist aqueous solution is added dropwise to the L-arginine aqueous solution and the polylysine aqueous solution, shaken at room temperature for self-assembly, centrifuged and washed to obtain the nanoparticle core; wherein the volume ratio of the TLR3 agonist aqueous solution, the L-arginine aqueous solution and the polylysine aqueous solution is 60:(80-110):(110-130).
5. The preparation method according to claim 4, characterized in that: The concentration of the TLR3 agonist aqueous solution is 2 mg / mL, the concentration of the L-arginine aqueous solution is 5 mg / mL, and the concentration of the polylysine aqueous solution is 2 mg / mL; The shaking conditions are: rotation speed 3000 rpm, time 30-60 min; the centrifugal conditions are: rotation speed 10000 rpm, time 10-20 min.
6. The preparation method according to claim 3, characterized in that: The method for preparing the nanoparticle shell specifically comprises the following steps: The intermediate product I is prepared by mixing hyaluronic acid, adipic acid dihydrazide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, dialyzing and freeze-drying. N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride are reacted with the sonosensitizer, and then reacted with the intermediate product I, dialyzed, and freeze-dried to obtain the nanoparticle shell.
7. The preparation method according to claim 6, characterized in that: The mass ratio of the hyaluronic acid, the adipic acid dihydrazide and the 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride is 100:(200-240):(20-30); The mass ratio of the N-hydroxysuccinimide, the 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and the sonosensitizer is 30:(35-45):30, and the mass ratio of the sonosensitizer to the intermediate product I is 30:
100.
8. The preparation method according to claim 3, characterized in that: The volume ratio of the nanoparticle core to the nanoparticle shell is 2:3; The mixing conditions are: rotation speed 500 rpm, stirring time 10-12h; The ultrasonic conditions are: using a 3 mm probe, a power of 20%, a treatment time of 1 min, and ultrasonicating for 5 s every 5 s.
9. Use of the nanoparticles as claimed in claim 1 or 2 in any of the following: (1) Application in the preparation of products that enhance the body's immune response; (2) Application in the preparation of products for treating tumors or inhibiting tumor metastasis and recurrence.
10. The use according to claim 9, characterized in that The tumors include colorectal cancer.
Citation Information
Patent Citations
Lung cancer targeted self-assembly nano-drug for enhancing sonodynamic therapy as well as preparation and application of lung cancer targeted self-assembly nano-drug
CN113018276A
Nanoparticles cooperating with NO gas treatment and enhancing sonodynamic therapy effect as well as preparation method and application of nanoparticles
CN113941010A
Construction of photosensitive nano-micelle capable of inducing M1 type polarization of tumor-associated macrophages and anti-tumor application of photosensitive nano-micelle
CN114404364A
Preparation method of tumor microenvironment response type nano drug delivery system
CN118267473A
System and method for sonosensitized cancer immunotherapy with nanoparticles
US20210169979A1
Cited By
Nanofiber hydrogel for sonodynamic / chemical dynamic synergistic anti-tumor as well as preparation method and application of nanofiber hydrogel
CN122320857A
